Related Experiment Video
Updated: Mar 6, 2026

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles
Published on: November 17, 2018
Neoepitopes as cancer immunotherapy targets: key challenges and opportunities
Cory A Brennick1, Mariam M George1, William L Corwin1
1Department of Immunology, & Carole & Ray Neag Comprehensive Cancer Center, University of Connecticut, School of Medicine, Farmington, CT 06030-1601, USA.
Abstract:
Over the last half century, it has become well established that cancers can elicit a host immune response that can target them with high specificity. Only within the last decade, with the advances in high-throughput gene sequencing and bioinformatics approaches, are we now on the forefront of harnessing the host's immune system to treat cancer. Recently, some strides have been taken toward understanding effective tumor-specific MHC I restricted epitopes or neoepitopes. However, many fundamental questions still remain to be addressed before this therapy can live up to its full clinical potential. In this review, we discuss the major hurdles that lie ahead and the work being done to address them.
Insights
Harnessing the immune system to treat cancer shows promise. This review explores challenges and ongoing research in developing effective cancer immunotherapies targeting tumor-specific epitopes.
Area of Science:
- Immunology
- Oncology
- Bioinformatics
Background:
- Cancers can trigger specific host immune responses.
- Recent advances in gene sequencing and bioinformatics enable cancer immunotherapy.
- Understanding tumor-specific epitopes is crucial for effective treatment.
Purpose of the Study:
- To review the current challenges in cancer immunotherapy.
- To discuss ongoing research addressing these hurdles.
- To highlight the potential of harnessing the immune system for cancer treatment.
Main Methods:
- Review of recent scientific literature.
- Analysis of high-throughput gene sequencing data.
- Bioinformatic approaches for epitope identification.
Main Results:
- Significant progress in identifying tumor-specific MHC I restricted epitopes (neoepitopes).
- Several fundamental questions remain unanswered for clinical application.
- Active research is underway to overcome existing obstacles.
Conclusions:
- Cancer immunotherapy holds great clinical potential.
- Further research is essential to address remaining challenges.
- Overcoming hurdles will unlock the full therapeutic capacity of cancer immunotherapies.
More Related Videos
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
08:02In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells
Published on: September 23, 2021
Related Concept Videos
Tumor Immunotherapy
Mitogens and the Cell Cycle
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Clinical Applications of Epidermal Stem Cells
The Tumor Microenvironment